BS_JT82QGXF
medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- medulloblastoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- medulloblastoma
- overall_survival_months
- 112.6149802890933
- age_years
- 9.337
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.465
- PANCREAS_BETA_CELLS+0.359
- G2M_CHECKPOINT+0.351
- KRAS_SIGNALING_DN+0.285
- SPERMATOGENESIS+0.239
- WNT_BETA_CATENIN_SIGNALING+0.133
- ANGIOGENESIS+0.064
- APICAL_SURFACE+0.057
- MITOTIC_SPINDLE+0.032
- MYC_TARGETS_V2-0.054
Top 10 suppressed
- PROTEIN_SECRETION-0.643
- INTERFERON_ALPHA_RESPONSE-0.610
- OXIDATIVE_PHOSPHORYLATION-0.571
- CHOLESTEROL_HOMEOSTASIS-0.521
- INTERFERON_GAMMA_RESPONSE-0.509
- ADIPOGENESIS-0.507
- ANDROGEN_RESPONSE-0.494
- MTORC1_SIGNALING-0.470
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.469
- TGF_BETA_SIGNALING-0.446
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG459 | — | — | 0.935 |
| 2 | SRR22247242 | — | cohortSC | 0.927 |
| 3 | BS_44A3ES23 | medulloblastoma | — | 0.926 |
| 4 | BS_JVW2JJ39 | high-grade glioma | — | 0.922 |
| 5 | BS_4E1G7E3G | ATRT | — | 0.919 |
| 6 | BS_HHPA8NJ2 | medulloblastoma | — | 0.916 |
| 7 | SRR6013541 | — | cohortSQ1 | 0.912 |
| 8 | BS_77317DY4 | medulloblastoma | — | 0.911 |
| 9 | 266352 | EPN | EPN Tumor | 0.911 |
| 10 | BS_TA9WP4TH | medulloblastoma | — | 0.911 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.465 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.359 | Cobimetinib | — uncovered |
| G2M_CHECKPOINT | 0.351 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.285 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.239 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.133 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.064 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.057 | Temsirolimus | — uncovered |
| MITOTIC_SPINDLE | 0.032 | Inavolisib | — uncovered |